Abstract

The JAK2/STAT signaling pathway mediates cytokine receptor signals that are involved in cell growth, survival and homeostasis. JAK2 is a member of the Janus kinase (JAK) family and aberrant JAK2/STAT is involved with various diseases, making the pathway a therapeutic target. The similarity between the ATP binding site of protein kinases has made development of specific inhibitors difficult. Current JAK2 inhibitors are not selective and produce unwanted side effects. It is thought that increasing selectivity of kinase inhibitors may reduce the side effects seen with current treatment options. Thus, there is a great need for a selective JAK inhibitor. In this study, we identified a JAK2 specific inhibitor. We first identified key pharmacological interactions in the JAK2 binding site by analyzing known JAK2 inhibitors. Then, we performed structure-based virtual screening and filtered compounds based on their pharmacological interactions and identified compound NSC13626 as a potential JAK2 inhibitor. Results of enzymatic assays revealed that against a panel of kinases, compound NSC13626 is a JAK2 inhibitor and has high selectivity toward the JAK2 and JAK3 isozymes. Our cellular assays revealed that compound NSC13626 inhibits colorectal cancer cell (CRC) growth by downregulating phosphorylation of STAT3 and arresting the cell cycle in the S phase. Thus, we believe that compound NSC13626 has potential to be further optimized as a selective JAK2 drug.

Original languageEnglish
Pages (from-to)1379
JournalFrontiers in Pharmacology
Volume9
DOIs
Publication statusPublished - 2018

Fingerprint

Janus Kinases
Phosphotransferases
Binding Sites
Pharmacology
Cytokine Receptors
Enzyme Assays
Growth
S Phase
Protein Kinases
Isoenzymes
Colorectal Neoplasms
Cell Survival
Cell Cycle
Carrier Proteins
Homeostasis
Down-Regulation
Adenosine Triphosphate
Phosphorylation
Pharmaceutical Preparations
Therapeutics

Cite this

A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions. / Lin, Tony Eight; HuangFu, Wei-Chun; Chao, Min-Wu; Sung, Tzu-Ying; Chang, Chao-Di; Chen, Yi-Ying; Hsieh, Jui-Hua; Tu, Huang-Ju; Huang, Han-Li; Pan, Shiow-Lin; Hsu, Kai-Cheng.

In: Frontiers in Pharmacology, Vol. 9, 2018, p. 1379.

Research output: Contribution to journalArticle

Lin, Tony Eight ; HuangFu, Wei-Chun ; Chao, Min-Wu ; Sung, Tzu-Ying ; Chang, Chao-Di ; Chen, Yi-Ying ; Hsieh, Jui-Hua ; Tu, Huang-Ju ; Huang, Han-Li ; Pan, Shiow-Lin ; Hsu, Kai-Cheng. / A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions. In: Frontiers in Pharmacology. 2018 ; Vol. 9. pp. 1379.
@article{1ebb9b521ed0453bb4c4e7815a9b658b,
title = "A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions",
abstract = "The JAK2/STAT signaling pathway mediates cytokine receptor signals that are involved in cell growth, survival and homeostasis. JAK2 is a member of the Janus kinase (JAK) family and aberrant JAK2/STAT is involved with various diseases, making the pathway a therapeutic target. The similarity between the ATP binding site of protein kinases has made development of specific inhibitors difficult. Current JAK2 inhibitors are not selective and produce unwanted side effects. It is thought that increasing selectivity of kinase inhibitors may reduce the side effects seen with current treatment options. Thus, there is a great need for a selective JAK inhibitor. In this study, we identified a JAK2 specific inhibitor. We first identified key pharmacological interactions in the JAK2 binding site by analyzing known JAK2 inhibitors. Then, we performed structure-based virtual screening and filtered compounds based on their pharmacological interactions and identified compound NSC13626 as a potential JAK2 inhibitor. Results of enzymatic assays revealed that against a panel of kinases, compound NSC13626 is a JAK2 inhibitor and has high selectivity toward the JAK2 and JAK3 isozymes. Our cellular assays revealed that compound NSC13626 inhibits colorectal cancer cell (CRC) growth by downregulating phosphorylation of STAT3 and arresting the cell cycle in the S phase. Thus, we believe that compound NSC13626 has potential to be further optimized as a selective JAK2 drug.",
author = "Lin, {Tony Eight} and Wei-Chun HuangFu and Min-Wu Chao and Tzu-Ying Sung and Chao-Di Chang and Yi-Ying Chen and Jui-Hua Hsieh and Huang-Ju Tu and Han-Li Huang and Shiow-Lin Pan and Kai-Cheng Hsu",
year = "2018",
doi = "10.3389/fphar.2018.01379",
language = "English",
volume = "9",
pages = "1379",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions

AU - Lin, Tony Eight

AU - HuangFu, Wei-Chun

AU - Chao, Min-Wu

AU - Sung, Tzu-Ying

AU - Chang, Chao-Di

AU - Chen, Yi-Ying

AU - Hsieh, Jui-Hua

AU - Tu, Huang-Ju

AU - Huang, Han-Li

AU - Pan, Shiow-Lin

AU - Hsu, Kai-Cheng

PY - 2018

Y1 - 2018

N2 - The JAK2/STAT signaling pathway mediates cytokine receptor signals that are involved in cell growth, survival and homeostasis. JAK2 is a member of the Janus kinase (JAK) family and aberrant JAK2/STAT is involved with various diseases, making the pathway a therapeutic target. The similarity between the ATP binding site of protein kinases has made development of specific inhibitors difficult. Current JAK2 inhibitors are not selective and produce unwanted side effects. It is thought that increasing selectivity of kinase inhibitors may reduce the side effects seen with current treatment options. Thus, there is a great need for a selective JAK inhibitor. In this study, we identified a JAK2 specific inhibitor. We first identified key pharmacological interactions in the JAK2 binding site by analyzing known JAK2 inhibitors. Then, we performed structure-based virtual screening and filtered compounds based on their pharmacological interactions and identified compound NSC13626 as a potential JAK2 inhibitor. Results of enzymatic assays revealed that against a panel of kinases, compound NSC13626 is a JAK2 inhibitor and has high selectivity toward the JAK2 and JAK3 isozymes. Our cellular assays revealed that compound NSC13626 inhibits colorectal cancer cell (CRC) growth by downregulating phosphorylation of STAT3 and arresting the cell cycle in the S phase. Thus, we believe that compound NSC13626 has potential to be further optimized as a selective JAK2 drug.

AB - The JAK2/STAT signaling pathway mediates cytokine receptor signals that are involved in cell growth, survival and homeostasis. JAK2 is a member of the Janus kinase (JAK) family and aberrant JAK2/STAT is involved with various diseases, making the pathway a therapeutic target. The similarity between the ATP binding site of protein kinases has made development of specific inhibitors difficult. Current JAK2 inhibitors are not selective and produce unwanted side effects. It is thought that increasing selectivity of kinase inhibitors may reduce the side effects seen with current treatment options. Thus, there is a great need for a selective JAK inhibitor. In this study, we identified a JAK2 specific inhibitor. We first identified key pharmacological interactions in the JAK2 binding site by analyzing known JAK2 inhibitors. Then, we performed structure-based virtual screening and filtered compounds based on their pharmacological interactions and identified compound NSC13626 as a potential JAK2 inhibitor. Results of enzymatic assays revealed that against a panel of kinases, compound NSC13626 is a JAK2 inhibitor and has high selectivity toward the JAK2 and JAK3 isozymes. Our cellular assays revealed that compound NSC13626 inhibits colorectal cancer cell (CRC) growth by downregulating phosphorylation of STAT3 and arresting the cell cycle in the S phase. Thus, we believe that compound NSC13626 has potential to be further optimized as a selective JAK2 drug.

U2 - 10.3389/fphar.2018.01379

DO - 10.3389/fphar.2018.01379

M3 - Article

C2 - 30564118

VL - 9

SP - 1379

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

ER -